| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
010-82848833 400-666-7788 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:ZonisaMide-13C2-15N
CAS:1188265-58-8
Package:10Mg,1Mg
|
| Company Name: |
Cato Research Chemicals Inc.
|
| Tel: |
020-81960175 |
| Email: |
min.he@cato-chem.com |
| Products Intro: |
Product Name:ZonisaMide-13C2-15N
CAS:1188265-58-8
Purity:95% Package:25Mg, 50Mg
|
| Company Name: |
Shanghai QianYan Bio-technology Co., Ltd
|
| Tel: |
02781293128 |
| Email: |
orders@biochemsafebuy.com |
| Products Intro: |
Product Name:Zonisamide-13C2-15N
CAS:1188265-58-8
Purity:>98% .NMR+LCMS Package:50Mg/100Mg/500Mg/1g/5g/10g/
|
| Company Name: |
Hubei Yangxin Medical Technology Co., Ltd.
|
| Tel: |
15374522761 |
| Email: |
3003392093@qq.com |
| Products Intro: |
Product Name:Zonisamide-13C2-15N(Amide)
CAS:1188265-58-8
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:Zonisamide-13C2,15N
CAS:1188265-58-8
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
|
| | ZONISAMIDE-13C2-15N Basic information |
| | ZONISAMIDE-13C2-15N Chemical Properties |
| Melting point | 158 - 160°C | | storage temp. | Refrigerator | | solubility | DMSO (Sparingly), Methanol (Slightly) | | form | Solid | | color | Off-White to Light Yellow |
| | ZONISAMIDE-13C2-15N Usage And Synthesis |
| Description | Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent. It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml. In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current. Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively. In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid (HVA; ) or dihydroxyphenyl acetic acid (DOPAC; ), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson''s disease. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. | | Uses | Zonisamide-13C2-15N is the labeled analogue of Zonisamide (Z700000), a sulfonamide antiseizure agent; blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents. Heterocyclic methanesulfonide with anticonvulsant properties. The compound is under investigation for potential therapeutic use as an antiepileptic drug. Anticonvulsant. |
| | ZONISAMIDE-13C2-15N Preparation Products And Raw materials |
|